ES2401855T3 - Compuestos heterocíclicos, activos como inhibidores de beta-lactamasas - Google Patents

Compuestos heterocíclicos, activos como inhibidores de beta-lactamasas Download PDF

Info

Publication number
ES2401855T3
ES2401855T3 ES10177533T ES10177533T ES2401855T3 ES 2401855 T3 ES2401855 T3 ES 2401855T3 ES 10177533 T ES10177533 T ES 10177533T ES 10177533 T ES10177533 T ES 10177533T ES 2401855 T3 ES2401855 T3 ES 2401855T3
Authority
ES
Spain
Prior art keywords
oxo
trans
diazabicyclo
octane
sulfooxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10177533T
Other languages
English (en)
Spanish (es)
Inventor
Jozsef Aszodi
Claude Fromentin
Maxime Lampilas
David Alun Rowlands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novexel SA
Original Assignee
Novexel SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2401855(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novexel SA filed Critical Novexel SA
Application granted granted Critical
Publication of ES2401855T3 publication Critical patent/ES2401855T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES10177533T 2002-01-28 2003-01-27 Compuestos heterocíclicos, activos como inhibidores de beta-lactamasas Expired - Lifetime ES2401855T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200951 2002-01-28
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (1)

Publication Number Publication Date
ES2401855T3 true ES2401855T3 (es) 2013-04-25

Family

ID=27619669

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10177533T Expired - Lifetime ES2401855T3 (es) 2002-01-28 2003-01-27 Compuestos heterocíclicos, activos como inhibidores de beta-lactamasas
ES03709903T Expired - Lifetime ES2356813T3 (es) 2002-01-28 2003-01-27 Nuevos compuestos heterocíclicos, activos como inhibidores de beta-lactamasas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES03709903T Expired - Lifetime ES2356813T3 (es) 2002-01-28 2003-01-27 Nuevos compuestos heterocíclicos, activos como inhibidores de beta-lactamasas.

Country Status (44)

Country Link
US (4) US7612087B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP1480644B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4472346B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100979079B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN100563653C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR038234A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE484281T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003214335B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2016C069I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0307267B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2474043C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2011000009A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5601014A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (2) CR7387A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (3) CY1111061T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60334527D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1480644T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA007220B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP045193A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2401855T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (2) FR2835186B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20040686B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUS1600055I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL163167A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JO (1) JO2646B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1480644I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA26351A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04006621A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY140638A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300847I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO335195B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ533936A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA12761A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20030969A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL220725B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT1480644E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS52137B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI2279737T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TNSN04137A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI293071B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA80271C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY27626A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003063864A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200405607B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
JP5180836B2 (ja) 2005-12-07 2013-04-10 バジリア ファルマスーチカ アーゲー モノバクタム系抗生物質とβ−ラクタマーゼ系阻害剤との有用な組み合わせ
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
CA2667816A1 (en) * 2006-10-23 2008-05-02 Irm Llc Compositions and methods for inhibiting cathepsin proteases
JP5323063B2 (ja) * 2007-05-31 2013-10-23 塩野義製薬株式会社 オキシイミノ化合物およびその使用
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
EP2231667B1 (en) * 2008-01-18 2013-09-04 Merck Sharp & Dohme Corp. Beta-lactamase inhibitors
US20110046101A1 (en) * 2008-03-17 2011-02-24 Dmitrienko Gary I Bate-lactamase inhibitors
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
WO2009151152A1 (en) * 2008-06-11 2009-12-17 Shionogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
US8680136B2 (en) 2010-08-10 2014-03-25 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
DK2657234T3 (da) * 2010-12-22 2017-02-20 Meiji Seika Pharma Co Ltd Optisk aktivt diazabicyclooctanderivat og fremgangsmåde til fremstilling heraf
CN103649051B (zh) * 2011-06-17 2016-04-13 阿斯利康(瑞典)有限公司 制备包括反-7-氧代-6-(磺基氧基)-1,6-二氮杂二环[3,2,1]辛烷-2-甲酰胺的杂环化合物及其盐的方法
MX348974B (es) * 2011-08-27 2017-07-04 Wockhardt Ltd Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
AU2012310136B2 (en) * 2011-09-13 2016-07-07 Wockhardt Limited Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
KR20140144254A (ko) 2012-03-30 2014-12-18 큐비스트 파마슈티컬즈 인코포레이티드 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 β-락타마제 억제제
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
TW201343646A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc 異□唑β－內醯胺酶抑制劑
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
PT2857401T (pt) * 2012-05-30 2019-11-19 Meiji Seika Pharma Co Ltd Novo inibidor de β-lactamase e método para a produção do mesmo
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20150203503A1 (en) * 2012-08-25 2015-07-23 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9132140B2 (en) 2013-01-04 2015-09-15 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2970338A1 (en) 2013-03-14 2016-01-20 Merck Sharp & Dohme Corp. Crystalline form of a beta-lactamase inhibitor
ES2793201T3 (es) 2013-09-24 2020-11-13 Meiji Seika Pharma Co Ltd Procedimiento de producción de derivados y productos intermedios de diazabiciclooctano
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
NZ757220A (en) 2013-10-08 2021-12-24 Meiji Seika Pharma Co Ltd Crystalline forms of diazabicyclooctane derivative and production process thereof
US20170065566A1 (en) * 2014-02-20 2017-03-09 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
EP3604316B1 (en) 2014-05-05 2023-12-06 Melinta Therapeutics, Inc. Synthesis of boronate salts
ES2985626T3 (es) 2014-05-05 2024-11-06 Melinta Therapeutics Inc Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
US9963467B2 (en) 2014-05-19 2018-05-08 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
CA2952968A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
RS58429B1 (sr) 2014-11-17 2019-04-30 Entasis Therapeutics Ltd Kombinovana terapija za lečenje rezistentnih bakterijskih infekcija
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10294224B2 (en) 2014-12-05 2019-05-21 Meiji Seika Pharma Co., Ltd. Lyophilized composition of a diazabicyclooctane compound and process of producing the same
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2016257338B2 (en) * 2015-05-07 2020-03-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CN107531709B (zh) * 2015-09-16 2020-10-23 吉林四环制药有限公司 β-内酰胺酶抑制剂及其用途
JP2018530553A (ja) 2015-10-02 2018-10-18 レゴケム バイオサイエンシズ， インク．Ｌｅｇｏｃｈｅｍ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． β−ラクタマーゼを阻害するための組成物及び方法
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
ES2734773T3 (es) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Compuestos de dihidrooxadiazina para tratar infecciones y cáncer
UA124464C2 (uk) 2016-06-30 2021-09-22 Кьюпекс Біофарма, Інк. Похідні боронової кислоти та їх терапевтичні застосування
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
ES2927986T3 (es) 2016-09-16 2022-11-14 Entasis Therapeutics Ltd Compuestos inhibidores de las betalactamasas
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
BR112019015834A2 (pt) 2017-02-06 2020-03-31 Mutabilis Compostos, composição farmacêutica, kit e uso de um composto ou uma composição
ES2907858T3 (es) 2017-05-08 2022-04-26 Entasis Therapeutics Inc Compuestos y métodos para el tratamiento de infecciones bacterianas
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited PROCESS FOR O-SULFONATION OF 1,6-DIAZABICYCLO [3.2.1] OCTANE COMPOUNDS
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
US12016868B2 (en) 2018-04-20 2024-06-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
IL280770B2 (en) 2018-08-09 2024-05-01 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
WO2022047603A1 (en) 2020-09-01 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Beta-lactamase inhibitors and their preparation
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
US12410166B2 (en) 2021-05-07 2025-09-09 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
KR20240041506A (ko) 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
CN116375706B (zh) * 2023-02-22 2025-02-14 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
DE69016430T2 (de) 1989-06-09 1995-06-01 Upjohn Co Heterozyklische amine mit zns-wirksamkeit.
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
EP1227103B1 (en) 1993-09-29 2006-07-26 Nabi Ring-expanded nucleosides and nucleotides
NZ274915A (en) * 1993-12-29 1997-11-24 Pfizer N-(hetero)aryl methyl diazabicycloalkane derivatives
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
IL124912A0 (en) * 1996-01-03 1999-01-26 Smithkline Beecham Plc Carbamoyloxy derivatives of mutiline and their use as antibacterials
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
US6329389B1 (en) 1998-04-08 2001-12-11 Takeda Chemical Industries, Ltd. Amine compounds, their production and use
EP1091944A1 (en) 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
CO5160344A1 (es) 1998-12-18 2002-05-30 Schering Corp Inhibidores de transferasa de proteina farnesilo
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CA2386517A1 (en) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
WO2001079206A1 (fr) 2000-04-18 2001-10-25 Sumitomo Pharmaceuticals Company, Limited Quinazolinediones tricycliques
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
WO2002067937A1 (en) 2001-02-22 2002-09-06 School Of Pharmacy, University Of London Indoline and tetrahydro-quinolines as prodrugs for tumour treatment
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
FR16C1019I1 (fr) 2017-02-03
CN100482225C (zh) 2009-04-29
EP1480644B1 (fr) 2010-10-13
DK1480644T3 (da) 2011-01-24
NO20043587L (no) 2004-08-27
RS52137B (en) 2012-08-31
PL220725B1 (pl) 2015-12-31
HRP20040686B1 (hr) 2013-02-28
EA200400981A1 (ru) 2005-02-24
NL300847I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-01-03
FR2835186B1 (fr) 2006-10-20
PL371601A1 (pl) 2005-06-27
CN1994301A (zh) 2007-07-11
EP2279737A1 (fr) 2011-02-02
HRP20040686A2 (en) 2004-12-31
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
BRPI0307267B8 (pt) 2021-05-25
KR100979079B1 (ko) 2010-08-31
PT1480644E (pt) 2011-01-17
CA2474043C (fr) 2011-08-02
TWI293071B (en) 2008-02-01
UA80271C2 (uk) 2007-09-10
CY1111061T1 (el) 2015-06-11
IL163167A (en) 2010-04-15
CO5601014A2 (es) 2006-01-31
ZA200405607B (en) 2005-09-28
PT2279737E (pt) 2013-02-01
SI2279737T1 (sl) 2013-07-31
NO2016024I1 (no) 2016-12-15
US20110245254A1 (en) 2011-10-06
CN100563653C (zh) 2009-12-02
CA2474043A1 (fr) 2003-08-07
ES2356813T3 (es) 2011-04-13
BRPI0307267B1 (pt) 2016-02-10
AR038234A1 (es) 2005-01-05
ATE484281T1 (de) 2010-10-15
CY2016042I1 (el) 2017-03-15
JP4472346B2 (ja) 2010-06-02
US20090215747A1 (en) 2009-08-27
CN1655781A (zh) 2005-08-17
LTPA2016037I1 (lt) 2017-01-10
BR0307267A (pt) 2004-12-07
OA12761A (fr) 2006-07-04
CY1114417T1 (el) 2016-08-31
NO335195B1 (no) 2014-10-20
JP2005523897A (ja) 2005-08-11
EA007220B1 (ru) 2006-08-25
FR16C1019I2 (fr) 2017-12-29
HK1105864A1 (zh) 2008-02-29
DE60334527D1 (de) 2010-11-25
WO2003063864A3 (fr) 2004-03-11
NO2016024I2 (no) 2016-12-15
LTC1480644I2 (lt) 2018-09-10
CL2011000009A1 (es) 2011-03-25
MY140638A (en) 2010-01-15
CR7387A (es) 2010-10-25
HUS1600055I1 (hu) 2017-01-30
WO2003063864A2 (fr) 2003-08-07
US20100048528A1 (en) 2010-02-25
BE2016C069I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-05-17
US7612087B2 (en) 2009-11-03
JO2646B1 (en) 2012-06-17
MXPA04006621A (es) 2004-10-04
DK2279737T3 (da) 2013-02-11
US20050020572A1 (en) 2005-01-27
AU2003214335B2 (en) 2007-04-05
SI1480644T1 (sl) 2011-03-31
ECSP045193A (es) 2004-08-27
AR100790A2 (es) 2016-11-02
MA26351A1 (fr) 2004-10-01
TNSN04137A1 (fr) 2007-03-12
CY2016042I2 (el) 2017-03-15
KR20040081473A (ko) 2004-09-21
CN101406471A (zh) 2009-04-15
CR20120356A (es) 2012-10-05
EP1480644A2 (fr) 2004-12-01
YU65804A (sh) 2006-08-17
HK1077205A1 (zh) 2006-02-10
EP2279737B1 (fr) 2012-10-31
FR2835186A1 (fr) 2003-08-01
NO2025027I1 (no) 2025-06-13
NZ533936A (en) 2007-05-31
UY27626A1 (es) 2003-08-29

Similar Documents

Publication Publication Date Title
ES2401855T3 (es) Compuestos heterocíclicos, activos como inhibidores de beta-lactamasas
ES2220793T3 (es) Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como anti-microbianos.
US20040097490A1 (en) Novel heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as B-lactamase inhibitors and antibacterials
BR122015020406B1 (pt) uso de compostos de formula i como inibidores de beta-lactamases e composições farmaceuticas
HK1077205B (en) Novel heterocyclic compounds which are active as inhibitors of beta+lactamases
HK1105864B (en) Heterocyclic compounds which are active as inhibitors of beta-lactamases